Pharmacologic Therapy for Cardiovascular Risk Reduction in Patients with the Metabolic Syndrome

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|20|31|5025-5038

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.20, Iss.31, 2014-01, pp. : 5025-5038

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sufficient Weight Reduction Decreases Cardiovascular Complications in Diabetic Patients with the Metabolic Syndrome

By  

Heart Drug, Vol. 5, Iss. 2, 2005-03 ,pp. : 68-74

Karger

Access to resources Recommend Favorite

Assessment of cardiovascular risk and simultaneous treatment of multiple risk factors is important in patients with metabolic syndrome

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 24, Iss. 9, 2008-09 ,pp. : 13-17

Adis International

Access to resources Recommend Favorite

Metabolic Syndrome: Cardiovascular Risk Assessment and Management

By Wong Nathan D.  

American Journal of Cardiovascular Drugs, Vol. 7, Iss. 4, 2007-01 ,pp. : 259-272

Adis International

Access to resources Recommend Favorite

The Association of Dysglycaemia and Cardiovascular Disease in Patients with Metabolic Syndrome

By Gong W   Yang Z   Ye W   Du Y   Lu B   Wang M   Li Q   Zhang W   Pan Y   Feng X   Zhou W   Zhang Y   Wen J   Yang Z   Yang Y   Zhu X   Hu R  

The Journal of International Medical Research, Vol. 37, Iss. 5, 2009-09 ,pp. : 1486-1492

Field House Publishing

Access to resources Recommend Favorite

Anticoagulant Therapy in Pregnant Patients with Metabolic Syndrome: A Review

By  

Current Pharmaceutical Biotechnology, Vol. 15, Iss. 1, 2014-06 ,pp. : 47-63

Bentham Science Publishers

Access to resources Recommend Favorite